VCYT
Veracyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.53
−4.79%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
23.7x
EV/EBITDA
22.9x
Market Cap
$3.42B
MomentumView details →
1D Return
−4.79%
YTD Return
+1.78%
RSI (14)
41.5
ValuationView details →
P/E (Fwd)
23.7x
EV/EBITDA
22.9x
Market Cap
$3.42B
RSI (14)
41.5
MomentumView details →
1D Return
−4.79%
YTD Return
+1.78%
SummaryUpdated Jun 1, 2026
Veracyte, Inc. (NASDAQ:VCYT) is a molecular diagnostics company founded in 2006 and headquartered in South San Francisco, California. Originally incorporated as Calderome, Inc., the company changed its name to Veracyte in March 2008 and went public in October 2013. Veracyte has evolved from a single-product thyroid cancer diagnostics company into a diversified genomic testing platform serving multiple cancer types including prostate, breast, lung, and colon cancers.
Similar companies
Latest newsMore news →
Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% during the first quarter, acquiring an additional 185,929 shares, according to its SEC filing.23d agoVeracyte launched Prosigna and TrueMRD products, which are expected to contribute to future growth but are excluded from 2026 guidance.26d agoVeracyte reported Q2 2026 results with 15% revenue growth, 23% adjusted EBITDA growth, and a 29.2% EBITDA margin, along with robust cash generation and no funded debt.26d ago